Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
about
Is lipid signaling through cannabinoid 2 receptors part of a protective system?The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker ratsDysregulation of the endocannabinoid system in obesity.Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice.Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats.Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells.Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.No compelling evidence that sibutramine prolongs life in rodents despite providing a dose-dependent reduction in body weightThe endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complicationsCannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell lineControlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation.Drug discovery in focal and segmental glomerulosclerosisRole of the endocannabinoid system in diabetes and diabetic complications.Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetesTargeting the endocannabinoid system: to enhance or reduce?Renal effects of chronic pharmacological manipulation of CB2 receptors in rats with diet-induced obesity.Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment.Marijuana Use and Estimated Glomerular Filtration Rate in Young Adults.Cannabinoids and the Kidney: Effects in Health and Disease.Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions.Role for cannabinoid receptors in human proximal tubular hypertrophy.Synthetic cannabinoids and acute kidney injury.Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome.Cannabinoid receptor 1 mediates palmitic acid-induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells.Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight.Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy.Obesity-Related CKD: When Kidneys Get the Munchies.Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD.Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.LH-21 and abnormal cannabidiol improve β-cell function in isolated human and mouse islets through GPR55-dependent and -independent signalling.Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.
P2860
Q24633122-B6041892-53A7-45AB-ABFC-530601839B1EQ28579415-5552116F-1E7A-40A5-99F4-75946FEB4045Q33345484-61081AB8-593E-4020-B587-204B03A3F984Q33451202-1AFCE332-104C-433C-AFBE-C5A2C67437D2Q33636763-4B5EBD2C-A4BE-4426-BDBF-E62EEA6078A2Q33750632-A0AE920F-0E4D-4DB2-B169-3B753637BD82Q34098258-C2214E97-D48B-44A1-9B77-8CFB16CF5EB3Q34098271-2B921A8D-D4F6-4B4A-8B35-C0CD99532A9FQ34290823-53D706B3-176C-45B1-9373-3DC4E9C2E200Q34504906-17D0429A-0134-4ACB-8D20-41D8A64C0448Q34582334-38B29158-3F58-4273-A8B0-18E4395A8B70Q34718769-5F14BB6E-4296-460D-99BB-5522FA3DC2ABQ34752048-212E4691-A714-4786-B22E-1455ED19501AQ34970367-5582F732-3505-46D9-9D32-BF9398F9C06FQ35951992-329CE784-F860-43CF-9F18-FD1B48FF5F20Q36032332-5D75DD87-69D0-44B7-A10E-510AD66EDC2DQ36373581-1E4F5421-D25E-4718-954D-25CBDEE31809Q36473356-D300A5D9-4B49-4BD0-B72A-ACCD2A174714Q36924116-1F219B49-3F95-4FB5-9309-213A5DDAEB4DQ37085532-B2928218-5BC7-4402-866D-38DE5CA6450DQ37094682-A16AB101-6543-42E8-9C8E-C6BBB676DA3CQ37150745-D7C5945C-A611-4D9E-9ECC-8FAC5F09054EQ37681996-B49E0197-A188-4D49-BDE5-C4E57105BF89Q38255902-8616C5FF-9496-4501-AF24-AA43E5772B42Q38398867-ABB0BF2A-E1CF-4002-A0CD-CAA5C0859AF8Q38651395-D381894B-7C40-4779-B3CC-C505F96CED7AQ38924783-02866985-11A1-4AC4-970D-6B641D7F279CQ39609590-F965420F-28F6-41FB-998D-59D5BB69623FQ41766626-EFAAE65C-0375-491F-91B9-A6E7B29A763AQ43052194-A91EAFD5-8B5E-4753-89E5-78F60E515D94Q43053240-15619CA2-CFF6-4450-BB33-424B2EDB5D9DQ43432897-96CFA4AC-D18D-426F-86F2-38C40979EE5DQ45288843-7FECAB20-154F-4CAB-AAF8-C329BFA93971Q47330379-1338FE7C-1854-4DC4-8195-9931D2760A3FQ47445806-45BA9362-A63E-4970-897F-732BCFC38F29Q47671197-69C4526E-EF12-45A5-B2AA-CF35BCA813EDQ47874226-31F97EB5-9FB8-488D-A920-3DE34A651943Q47985501-08526E58-0112-418E-A838-30F1C691868CQ48178388-00F53842-8772-41E3-BA74-46D9A1872F06Q51067641-2B273EC0-D2B7-404C-B465-67CE00DB6053
P2860
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Blockade of cannabinoid CB1 re ...... survival of obese Zucker rats.
@en
Blockade of cannabinoid CB1 re ...... survival of obese Zucker rats.
@nl
type
label
Blockade of cannabinoid CB1 re ...... survival of obese Zucker rats.
@en
Blockade of cannabinoid CB1 re ...... survival of obese Zucker rats.
@nl
prefLabel
Blockade of cannabinoid CB1 re ...... survival of obese Zucker rats.
@en
Blockade of cannabinoid CB1 re ...... survival of obese Zucker rats.
@nl
P2093
P921
P356
P1433
P1476
Blockade of cannabinoid CB1 re ...... survival of obese Zucker rats.
@en
P2093
C Cadrouvele
J-M Herbert
J-P Bidouard
J-P Maffrand
P2888
P304
P356
10.1038/SJ.KI.5002540
P407
P577
2007-09-19T00:00:00Z